Time to Initiated Antitumor Therapy for Tumor Patients With COVID19 Infection

Study Overview
=================
Brief Summary
-----------------
The goal of this observational study is to study the safety of initiation of antitumor therapy early after nucleic acid test turn negativity in tumor patients infected with COVID-19. The main questions aims to answer are: Whether initiation of antitumor therapy early after nucleic acid test turn negativity in tumor patients infected with COVID-19 increases adverse events related to antitumor therapy. Whether initiation of antitumor therapy early after nucleic acid test turn negativity in tumor patients infected with COVID-19 increases risk of re-infection of COVID-19. How initiation of antitumor therapy early after nucleic acid test turn negativity in tumor patients infected with COVID-19 affects QoL of tumor patients Participants will be asked to answer the question about: the severity and duration of COVID-19 symptoms the date of diagnosis of COVID-19 the date of negative nucleic acid test the QoL of life before infection with COVID-19, during infection of COVID-19, after nucleic acid test negativity and receiving antitumor therapy

Official Title
-----------------
When to Initiation Antitumor Therapy for Tumor Patients With COVID19 Infection

Conditions
-----------------
Tumor, COVID-19

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Tumor patients diagnosed with COVID-19 infection at our center from December 1, 2022 to May 31. COVID-19 was confirmed by antigen testing or nucleic acid testing. Tumor was confirmed by pathology. Patients received systemic antitumor therapy after infected with COVID-19. Exclusion Criteria: COVID-19 was not confirmed by antigen testing or nucleic acid testing Tumor was not confirmed by pathology Patients did not receive systemic antitumor therapy Patients died before receiving systemic antitumor therapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| A<br>Tumor patients infected with COVID-19 | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of adverse events after antitumor therapy | Incidence of adverse events after antitumor therapy, including hematologic toxicity,gastrointestinal adverse event, hepatobiliary adverse events, etc. | 28 days after antitumor therapy | 
| Re-infection of COVID-19 | Antigen testing or nucleic acid testing positive for COVID-19 | 28 days after antitumor therapy | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical manifestations of COVID-19 in tumor patients | Symptoms and lab abnormality of COVID-19 in tumor patients | Until nucleic acid testing turn negative | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Tumor patients, COVID-19, antitumor therapy